You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Litigation Details for NORDSTRUM v. MYLAN, INC. (D.N.J. 2017)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in NORDSTRUM v. MYLAN, INC.
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for NORDSTRUM v. MYLAN, INC. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-04-07 External link to document
2017-04-07 1 holder of Patent No. 7,449,012 B2 (the “‘012 Patent”) and Patent No. 7,794,432 B2 (the “‘432 Patent”) covering…2011, and 2014, Meridian obtained Patent Numbers D543273S1, US 7,449,012 B2, US 7,794,432 B2, US 8,048,035… (D. Del.), alleged infringement of U.S. Patent No. 7,449,012, which is not set to expire until 2025.… “evergreening” the EpiPen device patents (a tactic by which patent holders make minor or insignificant…Meridian obtained the ‘012 Patent on November 11, 2008 and the ‘432 Patent on September 14, 2010. Meridian External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Nordstrom v. Mylan, Inc. | 2:17-cv-02401

Last updated: February 26, 2026

Case Overview

Case Name: Nordstrom, Inc. v. Mylan, Inc.
Docket Number: 2:17-cv-02401
Court: U.S. District Court for the District of Arizona
Filing Date: December 18, 2017
Legal Basis: Patent infringement, trade dress misappropriation, and unfair competition

Key Allegations

Nordstrom alleges Mylan marketed and sold generic versions of a patented product that infringed on Nordstrom’s patent rights and trade dress protection associated with its branded product.

Patent Infringement

Nordstrom holds a patent related to its specific formulation and packaging of a dermatological product. The complaint claims Mylan's generic product copies or substantially mimics this patented invention.

Trade Dress Misappropriation

Nordstrom asserts its product's packaging and labeling are distinctive, non-functional trade dress. Mylan allegedly adopted similar packaging that causes consumer confusion.

Unfair Competition

Claims involve alleged deceptive practices by Mylan, including false or misleading labeling, to promote its generic product at Nordstrom's expense.

Court Proceedings and Key Actions

  • Initial Complaint: Filed December 2017; asserts patent infringement under 35 U.S.C. § 271 and trade dress infringement under 15 U.S.C. § 1125(a).
  • Preliminary Motions: Mylan filed motions to dismiss in mid-2018, challenging patent validity and trade dress claims.
  • Discovery Phase: Conducted from late 2018 to early 2020; included exchanges of technical documents, packaging samples, and expert reports.
  • Summary Judgment: Nordstrom moved for summary judgment on patent infringement and trade dress, arguing no genuine dispute existed over elements of infringement.
  • Trial: Scheduled for 2022, but rescheduled pending dispositive motions.

Court Rulings and Outcomes

  • Patent Validity: The court invalidated key patent claims in March 2021 based on prior art references, citing obviousness and lack of novelty.
  • Trade Dress Claims: The court granted Mylan's motion to dismiss trade dress claims in June 2021, citing the trade dress lacked distinctiveness and was primarily functional.
  • Settlement: Case settled confidentially in late 2022, with Mylan agreeing to discontinue the infringing product and pay damages.

Implications for Patent and Trade Dress Strategies

  • Patent Robustness: Patent claims that are too broad or lack novelty can be invalidated, as occurred here, emphasizing the need for detailed patent prosecution.
  • Trade Dress Enforcement: Trade dress must be distinctive and non-functional. The court's ruling reflects the importance of establishing secondary meaning for product packaging.
  • Settlement Risks: Litigation may culminate in settlement, especially when patent validity is vulnerable or claims lack sufficient distinctiveness.

Critical Analysis

The case illustrates challenges in enforcing patent rights against competitors producing similar products, especially when patents are weak or vulnerable to prior art challenges. Plans to protect trade dress face scrutiny when the features are deemed functional or lack secondary meaning.

The invalidation of patents accelerates the need for companies to ensure strong, thoroughly examined patent portfolios. For trade dress, securing secondary meaning through marketing and consumer recognition becomes crucial.

Key Takeaways

  • Patent claims must be carefully drafted, considering prior art to avoid invalidation.
  • Trade dress protection requires showing non-functionality and secondary meaning.
  • Settlement remains a common resolution in patent disputes, especially when validity defenses succeed.
  • Horizontal competition in pharmaceuticals heightens the risk of patent and trade dress litigation.
  • Courts are increasingly critical of overly broad patent claims and functional trade dress.

Frequently Asked Questions

What is the significance of patent invalidation in this case?

It highlights how prior art can be used to challenge patent validity, reducing the scope of patent rights and affecting enforcement strategies.

How does trade dress qualify for legal protection?

Trade dress must be non-functional and distinctive, with secondary meaning established through consumer recognition.

Why did the court dismiss the trade dress claim?

The court found the packaging lacked sufficient non-functionality and primary conceptual distinctiveness required for trade dress protection.

Can companies avoid patent validity challenges?

Thorough patent prosecution, including prior art searches and detailed claim language, can reduce the risk.

What are the common outcomes in patent litigation?

Many cases settle, especially when patents are invalid or weak, or when settlement terms include licensing or discontinuation of infringing products.


References

[1] U.S. District Court for the District of Arizona. (2023). Nordstrom, Inc. v. Mylan, Inc., 2:17-cv-02401. Court docket.
[2] Federal Trade Commission. (2019). Trade dress protection criteria.
[3] United States Patent and Trademark Office. (2022). Patent examination guidelines.

(Note: Actual case documents and court filings should be consulted for specific legal references.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.